Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;47(4):798-806.
doi: 10.1007/s00259-019-04460-y. Epub 2019 Aug 9.

The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases

Maarten L J Smits  1 , Mathijs G Dassen  1 , Jip F Prince  1 , Arthur J A T Braat  1 , Casper Beijst  1 , Rutger C G Bruijnen  1 , Hugo W A M de Jong  1 , Marnix G E H Lam  2
Affiliations

The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases

Maarten L J Smits et al. Eur J Nucl Med Mol Imaging. 2020 Apr.

Abstract

Purpose: As an alternative to technetium-99m-macroaggregated albumin (99mTc-MAA), a scout dose of holmium-166 (166Ho) microspheres can be used prior to 166Ho-radioembolization. The use of identical particles for pre-treatment and treatment procedures may improve the predictive value of pre-treatment analysis of distribution. The aim of this study was to analyze the agreement between 166Ho-scout and 166Ho-therapeutic dose in comparison with the agreement between 99mTc-MAA and 166Ho-therapeutic dose.

Methods: Two separate scout dose procedures were performed (99mTc-MAA and 166Ho-scout) before treatment in 53 patients. First, qualitative assessment was performed by two blinded nuclear medicine physicians who visually rated the agreement between the 99mTc-MAA, 166Ho-scout, and 166Ho-therapeutic dose SPECT-scans (i.e., all performed in the same patient) on a 5-point scale. Second, agreement was measured quantitatively by delineating lesions and normal liver on FDG-PET/CT. These volumes of interest (VOIs) were co-registered to the SPECT/CT images. The predicted absorbed doses (based on 99mTc-MAA and 166Ho-scout) were compared with the actual absorbed dose on post-treatment SPECT.

Results: A total of 23 procedures (71 lesions, 22 patients) were included for analysis. In the qualitative analysis, 166Ho-scout was superior with a median score of 4 vs. 2.5 for 99mTc-MAA (p < 0.001). The quantitative analysis showed significantly narrower 95%-limits of agreement for 166Ho-scout in comparison with 99mTc-MAA when evaluating lesion absorbed dose (- 90.3 and 105.3 Gy vs. - 164.1 and 197.0 Gy, respectively). Evaluation of normal liver absorbed dose did not show difference in agreement between both scout doses and 166Ho-therapeutic dose (- 2.9 and 5.5 Gy vs - 3.6 and 4.1 Gy for 99mTc-MAA and 166Ho-scout, respectively).

Conclusions: In this study, 166Ho-scout was shown to have a superior predictive value for intrahepatic distribution in comparison with 99mTc-MAA.

Keywords: Dosimetry; Holmium-166 microspheres; Radioembolization; SIRT; Technetium-99m-MAA.

PubMed Disclaimer

Conflict of interest statement

The Department of Radiology and Nuclear Medicine of the UMC Utrecht receives royalties and research support from Quirem Medical and Terumo. Marnix Lam is a consultant for BTG, Terumo and Quirem Medical. Maarten Smits has served as a speaker for Sirtex Medical, BTG and Terumo. Arthur Braat has served as a speaker for Sirtex Medical and Terumo. All other authors declare to have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Example of liver and tumor segmentation on FDG-PET (a) and co-registration on 99mTc-MAA (b), 166Ho-scout (c), and 166Ho-therapeutic dose (d) SPECT images. The delineated VOIs were extended with a margin of 1 cm; therefore, each target volume is surrounded by a second line
Fig. 2
Fig. 2
Inclusion flowchart of patient data
Fig. 3
Fig. 3
Box plot. Scores of the overall agreement between both 99mTc-MAA and 166Ho-scout and 166Ho-therapeutic dose of all 23 procedures are plotted in a box plot. Median and interquartile lines are indicated. Holmium scout dose performs significantly better than 99mTc-MAA (p < 0.001)
Fig. 4
Fig. 4
Example of discrepancy between 99mTc-MAA and 166Ho-therapeutic dose. Despite identical catheter positions (upper row), there is a remarkable difference in activity distribution between the three procedures. SPECT-CT (middle and lower row) shows that the activity distribution in the liver of 166Ho-scout is more similar to the therapy distribution than 99mTc-MAA. Overall agreement of 99mTc-MAA was rated 2.5 compared to 4.5 for 166Ho scout for this patient
Fig. 5
Fig. 5
Bland-Altman plots for lesion analyses. (1) Difference between 99mTc-MAA and 166Ho-therapeutic dose activity in each lesion is plotted against mean activity in each lesion. (2) Difference between 166Ho-scout and 166Ho-therapeutic dose activity in each lesion is plotted against mean activity in each lesion. The 95% limits of agreement (LoA) are indicated and surrounded by two dotted lines indicating the standard error of the 95% LoA
Fig. 6
Fig. 6
Bland-Altman plots for healthy-liver segmentation. (1) Difference between 99mTc-MAA and 166Ho-therapeutic dose activity is plotted against mean activity for each procedure. (2) Difference between 166Ho-scout and 166Ho-therapeutic dose activity is plotted against mean activity for each procedure. The 95% limits of agreement (LoA) are indicated and surrounded by two dotted lines indicating the standard error of the 95% LoA
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dhabuwala A, Lamerton P, Stubbs R. Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following selective internal radiation therapy (SIRT). BMC Nucl Med. 2005;5(7). - PMC - PubMed
    1. Wondergem M, Smits ML, Elschot M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic Radioembolization. J Nucl Med. 2013;54(8):1294–1301. doi: 10.2967/jnumed.112.117614. - DOI - PubMed
    1. Ulrich G, Dudeck O, Furth C, et al. Predictive value of Intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for Radioembolization with 90Y-microspheres. J Nucl Med. 2013;54(4):516–522. doi: 10.2967/jnumed.112.112508. - DOI - PubMed
    1. Ilhan H, Goritschan A, Paprottka P, et al. Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in Radioembolization of primary and secondary hepatic tumors. J Nucl Med. 2015;56(11):1654–1660. doi: 10.2967/jnumed.115.162685. - DOI - PubMed
    1. Seevinck PR, van de Maat GH, de Wit TC, et al. Magnetic resonance imaging-based radiation-absorbed dose estimation of 166Ho microspheres in liver radioembolization. Int J Radiat Oncol Biol Phys. 2012;83(3):437–444. doi: 10.1016/j.ijrobp.2011.12.085. - DOI - PubMed

Publication types

MeSH terms